One Line Pitch: Developing gene therapy platform to treat persons with hearing loss (466M people worldwide) there are currently no approved therapies for hearing loss.
Business Summary: RHI is generating positive proof of concept data on its lead gene therapy product (RHI100). RHI 100 qualifies as a rare disease and will pursue an "orphan status" regulatory path. RHI a privately held, pre-clinical, "C" Corp and has established a patent estate around its first 3 genetic targets. CEO's son (14yrs) has been diagnosed with permanent hearing loss due to a genetic condition.
Company Contacts
Address:
PO BOX 357391
GAINESVILLE, FL
US 32635
Website URL:
Contact Us:
(352) 682-8086
Connect With Us
Related Communities
